양극성 장애의 약물치료 가이드라인 비교
Comparative Review of Pharmacological Treatment Guidelines for Bipolar Disorder
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: Bipolar disorder displays a spectrum of manifestations, including manic, hypomanic, depressive, mixed, psychotic, and atypical episodes, contributing to its chronic nature and association with heightened suicide risk. Creating effective pharmacotherapy guidelines is crucial for managing bipolar disorder and reducing its prevalence. Treatment algorithms grounded in science have improved symptom management, but variations in recommended medications arise from research differences, healthcare policies, and cultural nuances globally. Methods: This study compares Korea’s bipolar disorder treatment algorithm with guidelines from the UK, Australia, and an international association. The aim is to uncover disparities in key recommended medications and their underlying factors. Differences in CYP450 genotypes affecting drug metabolism contribute to distinct recommended medications. Variances also stem from diverse guideline development approaches—expert consensus versus metaanalysis results—forming the primary differences between Korea and other countries. Results: Discrepancies remain in international guidelines relying on meta-analyses due to timing and utilized studies. Drug approval speeds further impact medication selection. However, limited high-quality research results are the main cause of guideline variations, hampering consistent treatment conclusions. Conclusion: Korea’s unique Delphi-based treatment algorithm stands out. To improve evidence-based recommendations, large-scale studies assessing bipolar disorder treatments for the Korean population are necessary. This foundation will ensure future recommendations are rooted in scientific evidence.
Abstract
Objective: Bipolar disorder displays a spectrum of manifestations, including manic, hypomanic, depressive, mixed, psychotic, and atypical episodes, contributing to its chronic nature and association with heightened suicide risk. Creating effective pharmacotherapy guidelines is crucial for managing bipolar disorder and reducing its prevalence. Treatment algorithms grounded in science have improved symptom management, but variations in recommended medications arise from research differences, healthcare policies, and cultural nuances globally. Methods: This study compares Korea’s bipolar disorder treatment algorithm with guidelines from the UK, Australia, and an international association. The aim is to uncover disparities in key recommended medications and their underlying factors. Differences in CYP450 genotypes affecting drug metabolism contribute to distinct recommended medications. Variances also stem from diverse guideline development approaches—expert consensus versus metaanalysis results—forming the primary differences between Korea and other countries. Results: Discrepancies remain in international guidelines relying on meta-analyses due to timing and utilized studies. Drug approval speeds further impact medication selection. However, limited high-quality research results are the main cause of guideline variations, hampering consistent treatment conclusions. Conclusion: Korea’s unique Delphi-based treatment algorithm stands out. To improve evidence-based recommendations, large-scale studies assessing bipolar disorder treatments for the Korean population are necessary. This foundation will ensure future recommendations are rooted in scientific evidence.
참고문헌 (23)
- Young Sup Woo, "Korean Medication Algorithm Project for Bipolar Disorder 2022, Fifth Revision: An Executive Summary", Clinical Psychopharmacology and Neuroscience, 20(4), pp.747~761 (2022), 대한정신약물학회[DOI]
- Kwak KP, "Bipolar Disorder", Journal of the Korean Medical Association, 50, pp.348~ (2007)
- 김세주, "급성기 양극성우울증 약물치료 전략", 신경정신의학, 57(4), pp.287~300 (2018), 대한신경정신의학회[DOI]
- "Health Insurance Review and Assessment S. ‘Bipolar disorder’ with severe mood swings, 40% of middle-aged people in their 40s and 50s"[URL]
- Cerimele MJ, "Bipolar Disorder and Population Health", Psychiatric Services, 68(2), pp.192~194 (2017)
- 김원, "한국형 양극성 장애 약물치료 알고리듬 2022: 총론", 신경정신의학, 61(2), pp.98~109 (2022), 대한신경정신의학회[DOI]
- American Psychiatric A, "Diagnostic and statistical manual of mental disorders : DSM-5", ~ (2013)
- Goodwin GM, "Evidence-based guidelines for treating bipolar disorder : Revised third edition recommendations from the British Association for Psychopharmacology", J Psychopharmacol, 30(6), pp.495~553 (2016)
- National Collaborating Centre for Mental H, "National Institute for Health and Care Excellence: Clinical Guidelines, in Bipolar Disorder: The NICE Guideline on the Assessment and Management of Bipolar Disorder in Adults, Children and Young People in Primary and Secondary Care", The British Psychological Society and The Royal College of Psychiatrists, ~ (2014)
- Yatham LN, "Canadian Network for Mood and Anxiety Treatments(CANMAT)and International Society for Bipolar Disorders(ISBD)2018 guidelines for the management of patients with bipolar disorder", Bipolar Disord, 20(2), pp.97~170 (2018)
- Malhi GS, "The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders", Australian & New Zealand Journal of Psychiatry, 55(1), pp.7~117 (2021)
- Fountoulakis KN, "The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 3: The Clinical Guidelines", Int J Neuropsychopharmacol, 20(2), pp.180~195 (2017)
- Jong Hyun Jeong, "Korean Medication Algorithm Project for Bipolar Disorder 2022: Comparisons with Other Treatment Guidelines", Clinical Psychopharmacology and Neuroscience, 21(1), pp.32~48 (2023), 대한정신약물학회[DOI]
- Korean College of Clinical P., "Clinical Pharmacology" (2022), Shin-il Books
- Shah N, "Clinical Practice Guidelines for Management of Bipolar Disorder", Indian J Psychiatry, 59(Suppl 1), pp.S51~S66 (2017)
- 우영섭, "정신과적 질환에 대한 새로운 약물요법", 대한의사협회지, 54(10), pp.1061~1069 (2011), 대한의사협회
- 정종현, "한국형 양극성 장애 약물치료 알고리듬 2022: 급속 순환형", 신경정신의학, 61(3), pp.204~213 (2022), 대한신경정신의학회[DOI]
- Konstantinou G, "Repetitive transcranial magnetic stimulation(rTMS)in bipolar disorder : A systematic review", Bipolar Disorders, 24(1), pp.10~26 (2022)
- Lin SK, "Racial", Ethnic Differences in the Pharmacokinetics of Antipsychotics : Focusing on East Asians, 2022, pp.12(9), 1362~
- Zhang X, "Association between aripiprazole pharmacokinetics and CYP2D6 phenotypes : A systematic review and meta-analysis", Journal of Clinical Pharmacy and Therapeutics, 44(2), pp.163~173 (2019)
- Koopmans AB, "Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19", Translational Psychiatry, 11(1), pp.141~ (2021)
- Veldic M, "Cytochrome P450 2C19 Poor Metabolizer Phenotype in Treatment Resistant Depression : Treatment and Diagnostic Implications", Frontiers in Pharmacology, 10, pp.83~ (2019)
- Berk M, "N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial", Biol Psychiatry, 64(6), pp.468~475 (2008)